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Background: Progression to metastasis is the leading cause of most cancer-related mortality; however, much
remains to be understood about what facilitates the spread of tumor cells. In the present study, we describe
a novel pathway in breast cancer that regulates epithelial-to-mesenchymal transition (EMT), motility, and invasiveness.
Methods: We examined nuclear factor I-C (NFI-C) expression in MCF10A human breast epithelial cells, MCF7
non-invasive breast cancer cells, and MDA-MB231 invasive breast cancer cells by real-time PCR and western
blotting. To investigate the loss- and gain-function of NFI-C, we determined whether NFI-C regulated KLF4
expression by real-time PCR, western blotting, and promoter assay. To understand the biological functions of
NFI-C, we observed cell invasion, migration, adhesion in human tumor cells by transwell assay, wound healing
assay, quantitative RT-PCR, cell adhesion assay, western blotting, and immunohistochemistry.
Results: We identified the downstream factors of NFI-C, such as KLF4 and E-cadherin, which play roles in
EMT. NFI-C is expressed in normal mammary gland or noninvasive breast cancer cells with epithelial characteristics.
NFI-C overexpression induced expression of KLF4 and E-cadherin, but not Slug, in breast cancer cells. NFI-C bound
directly to the KLF4 promoter and stimulated KLF4 transcriptional activity, thereby regulating E-cadherin expression
during tumorigenesis. Cells overexpressing NFI-C maintained their epithelial differentiation status, which could drive
mesenchymal-epithelial transition (MET) via the NFI-C-KLF4-E-cadherin axis in breast cancer cells. Consequently, NFI-C
suppressed EMT, migration, and invasion in breast cancer cells.
Conclusions: Our study reveals a novel signaling pathway that is important during breast cancer tumorigenesis: the
NFI-C-KLF4-E-cadherin pathway. The results indicate the important role of NFI-C in regulating KLF4 during tumorigenesis.
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The roles of Krüppel-like factor 4 (KLF4) have been
studied in many physiological processes, including devel-
opment, cytodifferentiation, and maintenance of normal
tissue homeostasis [1]. KLF4 is a zinc-finger transcrip-
tion factor which is usually expressed in growth-arrested
cells and differentiated cells of the colon, small intestine,
lung and testis [2]. Also, the expression of KLF4 is down-
regulated in several cancer types [3-5]. Database analysis
reveals a correlation between low KLF4 expression and an
increased incidence of malignant breast carcinoma [6].
KLF4 functions as both a transcriptional activator and a
repressor at various promoters in a context-dependent* Correspondence: jcapark@snu.ac.kr
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unless otherwise stated.manner. For example, KLF4 acts as a tumor suppressor by
binding to and repressing p53 promoters but activating
the promoter of p21, a gene involved in cell cycle inhib-
ition [7]. Interestingly, together with Oct4, Sox2 and
c-Myc, KLF4 is a pivotal factor in the generation of
induced pluripotent cells and is required for the epigen-
etic reprogramming of a somatic genome [8,9]. KLF4 is
necessary to maintain the proper morphology of epithelial
cells. While loss of KLF4 function induces EMT-like mor-
phological changes, forced expression of KLF4 in invasive
breast cancer cells induces epithelial differentiation by dir-
ectly repressing the expression of Snail1, a potent repres-
sor of E-cadherin gene expression, and directly binding to
the E-cadherin promoter and upregulating E-cadherin ex-
pression [10].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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scription factors, encoded by four genes in vertebrates
(termed NFI-A, NFI-B, NFI-C, and NFI-X), plays essen-
tial developmental roles in the transcriptional modula-
tion of various cell types [11]. In mammary epithelial
cells, NFI-C has an important role in prolactin signaling
with Jak2, which is independent of the signal transducers
and activators of transcription (Stat) pathway [12]. NFI-C
activates p53 and participates in the establishment of milk
protein gene expression during pregnancy [13]. Interest-
ingly, NFI-C expression indicates better prognosis in
breast cancer patients, because it is more highly expressed
in normal glandular cells and virtually absent from lymph
node metastases. It abolishes tumorigenicity, suppresses
EMT, and directly represses Forkhead box F1 (FoxF1), a
potent inducer of EMT, invasiveness, and tumorigenicity
[14,15]. Our previous report demonstrated that the cross-
talk between NFI-C and TGF-β1 signaling regulated cell
differentiation in odontoblasts [16]. Also, NFI-C regulates
E-cadherin expression via control of KLF4 during dentino-
genesis [17]. However, the precise functions of NFI-C in
EMT/METand tumorigenesis remain largely unknown.
Mesenchymal-epithelial transition (MET) events are
defined as those in which mesenchymal cells lose their
motile, migratory properties and multipolar or spindle-
shaped morphology and acquire cell polarity and adhe-
sion to become planar arrays of polarized cells called
epithelium. Both MET and epithelial-mesenchymal transi-
tion (EMT) occur in normal tissues, including gastrulating
and regenerating tissue, as well as abnormal tissues of fi-
brotic organs or tumors [18]. Indeed, EMT drives mam-
mary epithelial cells to de-differentiate into mammary
stem cells and cancer stem cells, which are mesenchymal-
like [19]. Thus, it is necessary to examine the relationship
between NFI-C and EMT/MET in that NFI-C plays an
antagonistic role of TGF-β1 signaling [16] and controls
KLF4 and E-cadherin [17].
Prior to this study, NFI-C were established as import-
ant regulators of KLF4, but the relationship between
NFI-C and KLF4 during tumorigenesis remained un-
clear. In the present study, we further investigated the




All experiments involving human cell lines were performed
according to the Dental Research Institute guidelines and
the Institutional Animal Care and Use Committees of
Seoul National University (SNU-111013-3). MCF7 cells
(ATCC, Rockville, MD) were grown and maintained in
DMEM (Gibco BRL, Carlsbad, CA) supplemented with
10% FBS and antibiotics in a 5% CO2 atmosphere at 37°C.
The immortalized human mammary epithelial cell line,MCF10A (ATCC), was cultured in complete MCF10A
growth media, composed of DMEM/nutrient mixture F12
(DMEM/F12, Gibco BRL) supplemented with 5% fetal calf
serum, 20 ng/ml EGF, 10 mg/ml insulin, 0.5 mg/ml hydro-
cortisone, and 100 ng/ml cholera toxin (Sigma-Aldrich,
St-Quentin Fallavier, France).
TGF-β stimulation
MCF10A or MCF7 cells were stimulated with TGF-β
(10 ng/ml, Invitrogen, Carlsbad, CA) at 37°C for 1 hr.
Plasmid constructs
The pCH-nuclear factor I-C (NFI-C) expression plasmid
was provided by Dr. R. M. Gronostajski (State University
of New York, Buffalo, Buffalo, NY). siRNAs were synthe-
sized (Integrated DNA Technologies, San Diego, CA)
based on 19 nucleotides of NFI-C (5′-CCG GTG AAG
AAG ACA GAG A-3′) and these siRNA plasmids were
prepared using the pSUPER-retro-neo-GFP retro virus
siRNA expression vector (OligoEngine, Seattle, WA) ac-
cording to the manufacturer’s instructions. KLF4 cDNAs
were amplified by PCR and subcloned into Flag-tagged
pMXs (Cell Biolabs, San Diego, CA). The pGL2-KLF4
and -E-cadherin plasmids were purchased from Origene
(Rockville, MD).
Real-time PCR analysis
Total RNA was extracted from MCF10A and MCF7 cells
as well as pulp tissue using TRIzol® reagent according to
the manufacturer’s instructions (Invitrogen). Total RNA
(2 μg) was reverse transcribed for 1 h at 50°C with
0.5 mg Oligo dT and 1 μl (50 IU) Superscript III enzyme
(Invitrogen) in a 20 μl reaction. One microliter of the
RT product was PCR amplified using the primer pairs.
For real-time PCR, the specific primers for NFI-C, Slug,
KLF4,Vimentin, E-cadherin, N-cadherin, and P-cadherin
are listed in Table 1. Real-time PCR was performed on
an ABI PRISM 7500 sequence detection system (Applied
Biosystems, Carlsbad, CA) using SYBR GREEN PCR
Master Mix (Takara Bio Inc., Otsu, Shiga, Japan) accord-
ing to the manufacturer’s instructions. PCR conditions
were 95°C for 1 min, 94°C for 15 sec, and 60°C for 34 sec
for 40 cycles. All reactions were run in triplicate and were
normalized to the housekeeping gene GAPDH. Relative
differences in PCR results were calculated using the com-
parative cycle threshold (CT) method.
Western blot analysis
To prepare whole cell extracts, cells were washed three
times with PBS, scraped into 1.5 ml tubes, and pelleted
by centrifugation at 12,000 rpm for 2 min at 4°C. After
removal of the supernatant, pellets were suspended in
lysis buffer [50 mM Tris-Cl (pH 7.4), 150 mM NaCl, 1%
NP-40, 2 mM EDTA (pH 7.4)] and incubated for 15 min
Table 1 Real-time PCR primer sequences
Gene name Primer
hNFI-C forward 5′-CGA CTT CCA GGA GAG CTT TG-3′
reverse 5′-GTT CAG GTC GTA TGC CAG GT-3′
hKLF4 forward 5′-CCC ACA CAG GTG AGA AAC CT-3′
reverse 5′-TTC TGG CAG TGT GGG TCA TA-3′
hSlug forward 5′-GAG CAT TTG CAG ACA GGT CA-3′
reverse 5′-CCT CAT GTT TGT GCA GGA GA-3′
hE-cadherin forward 5′-TGC CCA GAA AAT GAA AAA GG-3′
reverse 5′-GTG TAT GTG GCA ATG CGT TC-3′
hVimentin forward 5′-AAA GCG TGG CTG CCA AGA AC-3′
reverse 5′-GTG ACT GCA CCT GTC TCC GGT A-3′
hN-cadherin forward 5′-CGA ATG GAT GAA AGA CCC ATC C-3′
reverse 5′-GGA GCC ACT GCC TTC ATA GTC AA-3′
hP-cadherin forward 5′-GCA GAA GTC AGC GAG AAA GGA G-3′
reverse 5′-GGA GGA TGA AAC CAC CCT TCC A-3′
hGAPDH forward 5′- CCA TGG AGA AGG CTG GGG-3′
reverse 5′- CAA AGT TCT CAT GGA TGA CC-3′
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teins (30 μg) were separated by 10% SDS-PAGE and
transferred to nitrocellulose membranes (Schleicher &
Schuell BioScience, Dassel, Germany). Membranes were
blocked for 1 hr with 5% nonfat dry milk in PBS con-
taining 0.1% Tween 20 (PBS-T) and incubated overnight
at 4°C with the primary antibody diluted in PBS-T buffer
(1:1000). Rabbit polyclonal anti-NFI-C antibody was pro-
duced as described previously [20]. The mouse monoclo-
nal anti-HA (MMS-101P) antibody was purchased from
COVANCE (Emeryville, CA). Other antibodies, including
those against E-cadherin (sc-7870), N-cadherin (sc-7939),
Slug (sc-1539), and GAPDH (sc-25778), were purchased
from Santa Cruz Biotechnology (Santa Cruz Biotechnology,
CA). The rabbit polyclonal anti-E-cadherin (3195) antibody
was purchased from Cell Signaling Technology (Danvers,
MA). After washing, membranes were incubated for 1 hr
with anti-mouse (sc-2031), anti-rabbit (sc-2004), or anti-
goat (sc-2768) IgG secondary antibodies conjugated to
horseradish peroxidase (Santa Cruz Biotechnology). La-
beled protein bands were detected using an enhanced
chemiluminescence system (Dogen, Cambridge, MA). The
quantification analyses were performed using Image J
(http://imagej.nih.gov/ij/).
Transient transfection and luciferase assays
MCF7 cells were seeded in 12-well culture plates at a
density of 1.5 × 105 cells per well. Cells were transiently
transfected with reporter constructs using Metafectene
PRO reagent (Biontex, Planegg, Martinsried, Germany).
pGL2-KLF4 or -E-cadherin was transfected into cells with
NFI-A-, NFI-B-, NFI-C-, NFI-X-, KLF4-expressing constructs,or the NFI-C-siRNA construct. Following the addition of
luciferin (50 μl) to the cell lysate (50 μl), luciferase activ-
ity was determined using an analytical luminescence
luminometer according to the manufacturer’s instructions
(Promega, Madison, WI).
Chromatin Immunoprecipitation (ChIP) assays
After transfection with the indicated plasmid DNA using
the metafectene Pro reagent (Biontex), MDPC-23 cells
were treated with formaldehyde (1% final concentration)
for 10 min at 37°C, rinsed twice with cold PBS, and
swollen on ice in lysis buffer [1% SDS, 10 mM EDTA,
50 mM Tris–HCl (pH 8.1)] for 10 min. Nuclei were col-
lected and sonicated on ice. Supernatants were obtained
by centrifugation for 10 min and were diluted 10-fold in
ChIP dilution buffer [0.01% SDS, 1.1% Triton X-100,
1.2 mM EDTA, 16.7 mM Tris–HCl (pH 8.1), and
167 mM NaCl]. The fragmented chromatin mixture was
incubated for 4 h with anti-NFI-C antibody on a rotator
at 4°C. Protein A/G PLUS-agarose (30 μl; sc-2003, Santa
Cruz) was added and incubated at 4°C for 1 h with rotation
to collect the antibody/chromatin complex. The precipitated
chromatin complexes were recovered and reversed accord-
ing to the manufacturer’s protocol (Upstate Biotechnology,
Lake Placid, NY). The final DNA pellets were recovered and
analyzed by PCR using the specific primers for Klf4 (612 bp)
promoter region: forward, 5′-CTTAGAGAAATAAAAG
TAAAGCAGA-3′ and reverse, 5′-TTAGGTTTCCTCA
GAATATTTGTGA-3′. The following PCR conditions
were used: 94°C for 30 s; 55°C for 30 s; and 72°C for 1 min
for 35 cycles. PCR products were electrophoresed in 1%
agarose gels, stained with ethidium bromide, and visual-
ized under ultraviolet light.
DNA affinity precipitation (DNAP) assays
Transfected MCF7 cells were washed with ice-cold PBS,
collected by centrifugation, and resuspended in RIPA
buffer (50 mM Tris-Cl [pH 7.5], 150 mM NaCl, 1% Nonidet
P-40, 1 mM EDTA, 1 mM PMSF, 1 mM Na3VO4, and
1 mM NaF) supplemented with protease inhibitors (Roche
Molecular Biochemicals, Mannheim, Germany). Lysates
were rotated on a rotating platform for 30 min at 4°C and
purified by centrifugation at 13000 rpm for 5 min at 4°C.
Binding assays were performed by mixing nuclear extract
proteins (600 μg) and biotinylated specific wild type or
mutated NFI-C binding site oligonucleotides (6 μg) [17] of
KLF4 promoter in binding buffer (12% glycerol, 12 mM
HEPES-NaOH [pH 7.9], 4 mM Tris-Cl [pH 7.9], 60 mM
KCl, 1 mM EDTA, 1 mM DTT). Mutated positions in the
sequence are underlined [17]. Lysates were incubated at
room temperature for 30 min. Next, 60 μl of streptavidin-
agarose beads (Thermo Scientific, Rockford, IL) were
added. The mixture was incubated for 2 h at 4°C with ro-
tating. Beads were pelleted and washed three times with
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gonucleotides was detected by SDS-PAGE and immuno-
blotting using the mouse monoclonal anti-NFI-C antibody.
Adhesion assays
Stable cells expressing NFI-C or NFI-C-siRNA were
seeded in 96-well plates and incubated for 4 hr. At the
indicated times, plates were washed twice with PBS.
Cells were fixed with 4% paraformaldehyde for 30 min,
stained with crystal violet for 10 min, followed by the
addition of Tween 20 for 30 min. Finally, we measured
the OD at 595 nm.
Wound healing assays
After 24 hr of NFI-C or NFI-C-siRNA transfection or
TGF-β treatment, cells were harvested, seeded in 6-well
plates, and cultured until confluent. We used 200 μl pip-
ette tips to make a straight scratch, simulating a wound.
Cells were rinsed gently with PBS and cultured in fresh
complete media. Cells were imaged with a 10x objective on
a Leica DMLB microscope and acquired using QCapture
Software (QImaging Software).
Invasion assays
Cell migration was analyzed using Transwell assays (Corning
Inc., Corning, NY) with polycarbonate filters (pore size,
8 μm). Cells transfected with NFI-C or NFI-C-siRNA or
treated with TGF-β were seeded in the upper chamber at
a density of 1 × 105 cells/chamber in 100 μl media. The
lower chamber was filled with 600 μl DMEM. Plates were
incubated for 24 hr at 37°C, and cells in the upper cham-
ber were carefully removed using a cotton swab. Migrated
cells were fixed with 4% paraformaldehyde and stained
with Hoechst trihydrochloride (1:5000; Invitrogen) for
10 min. The number of invading cells was counted using
fluorescent microscopy. Four fields were randomly chosen,
and the number of penetrated cells was counted.
Gene expression omnibus (GEO)-database analysis
Gene expression profile data (GSE2429) of atypical
ductal hyperplasia with or without breast cancer cells was
downloaded from the National Center for Biotechnology
Information Gene Expression Omnibus (NCBI GEO)
database (http://www.ncbi.nlm.nih.gov/geo/). Only five
pairs of samples are available, one is derived from cancer
cells, whereas the other is derived from normal cells, and
each pair of samples represents eight breast cancer patients.
Tissue preparation and immunohistochemistry
The experimental protocol was also approved by the
Seoul National University’s Institutional Review Board
(S-D2011001). Malignant human breast tissues were ob-
tained retrospectively from the Seoul National University
Hospital archive (Seoul, Korea). Human breast tissueswere embedded in paraffin, and processed for immuno-
histochemistry. Sections were incubated overnight at 4°C
with rabbit polyclonal NFI-C and E-cadherin as the pri-
mary antibodies (dilutions of 1:100–1:200). Secondary
anti-rabbit IgG antibodies were added to the sections for
30 min at room temperature, and then reacted with the
avidin-biotin-peroxidase complex (Vector Laboratories,
Burlingame, CA). Signals were converted using a diamino-
benzidine kit (Vector Laboratories). Nuclei were stained
with hematoxylin.
Statistical analysis
Statistical analyses were performed using Student’s t-tests.
Statistical significance is denoted by *P < 0.01. All statis-
tical analyses were performed using SPSS software version
19.0 (IBM Corporation, Armonk, NY).
Results
NFI-C is expressed in normal epithelial cells, and its
expression is reduced during EMT
During tumor progression, carcinoma cells undergo EMT,
a process in which polarized epithelial cells undergo dy-
namic changes to lose their epithelial characteristics and
obtain a more motile fibroblastic phenotype, enabling
them to proceed with invasion and metastasis [21]. To as-
sess whether the presence of NFI-C in breast tumors has
any physiologic relevance, we examined the NFI-C and
E-cadherin protein expression in normal human breast
epithelial cells, MCF10A, non-invasive breast cancer cells,
MCF7, and invasive breast cancer cells, MDA-MB231 by
western blotting. NFI-C expression correlated with cellular
phenotype. Normal epithelial cells showed high expression
of NFI-C and E-cadherin protein; whereas, the noninvasive
and invasive cancer cells displayed little to no detectable ex-
pression of these two proteins (Figure 1A).
During mammary tumorigenesis, TGF-β signaling plays
an important role in EMT by facilitating the change from
cuboidal epithelial cells to elongated spindle-shaped cells
and causing decreased expression of epithelial markers and
enhanced expression of mesenchymal markers [22,23].
Based on the known roles of TGF-β during EMT in
MCF10A epithelial cells, we asked whether NFI-C expres-
sion is changed during EMT in these cells. Upon TGF-β-
induced EMT, a significant reduction in the level of NFI-C
and the epithelial marker E-cadherin indicated that
these cells lost some of their acquired epithelial features
(Figure 1B and C).
NFI-C maintains epithelial differentiation status and
mediates MET function in breast cancer cells
MET initiates and completes the invasion-metastasis
cascade of cancer cells [24]. Our previous results showed
that NFI-C induces MET during normal odontoblast dif-
ferentiation [17]. Therefore, we speculated that NFI-C
also regulates the balance between KLF4 and E-cadherin
Figure 1 TGF-β-mediated expression of NFI-C and E-cadherin.
(A) Expression of NFI-C and E-cadherin in MCF10A human breast
epithelial cells, MCF7 non-invasive breast cancer cells, and
MDA-MB231 invasive breast cancer cells analyzed by western
blotting. (B, C) Expression of NFI-C and E-cadherin in MCF10A
cells treated with TGF-β and control MCF10A cells analyzed by
real-time PCR (B) and western blotting (C).
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address this, we examined whether NFI-C could regulate
the transcription of KLF4 and E-cadherin and subse-
quently alter the expression of marker genes in MCF7
breast cancer cells. MCF7 cells were transfected with
NFI-C-expressing or NFI-C-siRNA constructs or treated
with TGF-β. NFI-C overexpression increased the tran-
scription of KLF4 and E-cadherin mRNAs, which play
an important role in the MET of cancer cells. In con-
trast, siRNA or TGF-β-mediated silencing of NFI-C de-
creased transcription of KLF4 and E-cadherin. However,
NFI-C expression levels did not significantly affect the
expression of N-cadherin compared with other mRNA
(Figure 2A). Slug (Snail2), a Snail family member, is the
dominant regulator of EMT initiation in vitro and in vivo,
as EMT is inhibited following Slug depletion [25]. KLF4
and another epithelial determinant, FoxA1, are directtranscriptional inhibitors of Slug expression in mouse and
human prostate cancer cells [26]. Interestingly, similar
with microarray data with pulp cells of Nfic knockout
mice [17], Slug mRNA was increased in NFI-C downregu-
lated cells (Figure 2A). Also, Vimentin and P-cadherin
mRNA was slightly increased in NFI-C downregulated
cells by siRNA or TGF-β (Figure 2A). In western blot ana-
lyses, although NFI-C overexpression did not alter the ex-
pression levels of Slug and N-cadherin, it enhanced the
expression of KLF4 and E-cadherin. Conversely, NFI-C in-
activation by siRNA suppressed E-cadherin expression and
induced Slug expression (Figure 2B). In addition, increasing
the concentration of NFI-C significantly enhanced the ex-
pression of luciferase reporter genes under the control of
the mouse KLF4 promoter. In contrast, depletion of NFI-C
using a specific siRNA suppressed promoter activity of the
KLF4 reporter construct in MCF7 cells (Figure 2C). NFI-C
overexpression augmented E-cadherin promoter activity;
whereas, siRNA-mediated NFI-C inactivation decreased
E-cadherin promoter activity (Figure 2D). Furthermore,
overexpression of NFI-C and KLF4 showed a synergistic
effect on E-cadherin transcription levels (Figure 2D).
In previous paper, Nfic binds to Klf4 promoter but not
to Klf4 promoter with the mutation of Nfic binding site
[17]. To confirm this data in tumor cells, we performed
ChIP assay with the primer of KLF4 promoter. The KLF4
promoter could be precipitated using an NFI-C-specific anti-
body in NFI-C-expressing cells but not in NFI-C-silenced
cells (Figure 2E). Similar with ChIP assay, DNAP assay
showed that the wild type of the KLF4 promoter bound
with NFI-C protein, but not NFI-C proteins with muta-
tions in these regions (Figure 2F). These studies suggest
that NFI-C regulates E-cadherin expression by controlling
the KLF4 promoter in cancer cells.
NFI-C suppresses EMT, migration, and invasion in breast
cancer cells
It is well-known that forced expression of TGF-β induces
EMT [27]. Breast cancer cell lines range from epithelial-
like with low invasiveness, to mesenchymal-like, which
exhibit high invasive capacity [28]. Therefore, we first in-
vestigated whether NFI-C expression levels correlate with
cellular phenotype in natural isolation. NFI-C-expressing
MCF10A cells grew as tightly packed patches of epithelial
sheets like normal MCF10A cells. In contrast, NFI-C-
siRNA-transfected or TGF-β-treated MCF10A cells were
longer, like mesenchymal cells (Figure 3A). In cell binding
assays, NFI-C-expressing MCF7 cells showed significantly
greater attachment than normal MCF7 cells on plates
(Figure 3B). Next, we asked whether NFI-C controlled mi-
gration and invasion of breast cancer cells by MET. In
wound healing assays, NFI-C enhanced MCF7 breast can-
cer cell migration. Conversely, ectopic NFI-C-siRNA or
TGF-β treatment reduced MCF7 cell motility (Figure 3C).
Figure 2 Effects of NFI-C overexpression and inactivation on the KLF4-E-cadherin signaling pathway in MCF7 breast cancer cells.
(A, B) Expression of NFI-C, KLF4, Slug, E-cadherin, Vimentin, N-cadherin, and P-cadherin was analyzed by real-time PCR (A) and western blotting
(B) in MCF7 cells transfected with NFI-C-expressing or NFI-C-siRNA constructs or treated with TGF-β. (C, D) Transcriptional activity of the KLF4
promoter and the E-cadherin promoter were evaluated by luciferase assays using NFI-C-expressing or NFI-C-siRNA constructs in MCF7 cells. Control
samples were transfected with only E-cadherin promoter constructs. Data are presented as the mean ± SD of triplicate experiments. * denotes
values significantly different from the control (P < 0.01). (E) NFI-C binding to the KLF4 promoter was investigated using ChIP assays after transfection
with NFI-C-expressing or NFI-C-siRNA constructs in MCF7 cells. (F) The NFI-C binding motif in the KLF4 promoter was confirmed by DNAP assay using
extracts from MCF7 cells that had been transfected with NFI-C-expressing or NFI-C-siRNA constructs. Biotinylated oligonucleotides corresponding to
the KLF4 promoter (WT or mutated) were used as probes. WT, wild type; MT, mutant type.
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decreased number of invasive MCF7 cells when transfected
with NFI-C-expressing constructs compared with control
cells, NFI-C-siRNA-transfected cells, or TGF-β-treated
cells (Figure 3D). These results indicated that NFI-C is cru-
cial for the inhibition of breast cancer cell migration and
invasion in vitro.
In cancer cells, we analyzed the invasion-related ex-
pression of NFI-C, KLF4, and E-cadherin using GEOdata. NFI-C, KLF4, and E-cadherin expression decreased
in atypical ductal hyperplasia with breast cancer cells
compared with atypical ductal hyperplasia without breast
cancer cells. Furthermore, we examined genes that are re-
lated to metastasis and invasion such as TIAM1 and SCAI.
Expression of TIAM1, an invasion factor, increased;
whereas, expression of SCAI, a suppressor of invasion,
decreased in atypical ductal hyperplasia with breast cancer
cells compared with atypical ductal hyperplasia without
Figure 3 Effects of NFI-C overexpression and inactivation on morphology, adhesion, migration, and invasion of breast cancer cells.
(A) Morphology of MCF10A cells when transfected with NFI-C-expressing or NFI-C-siRNA constructs, or treated with TGF-β. Images obtained using
phase-contrast microscopy (Magnification: 100×). (B) Cell adhesion was assessed in MCF7 cells transfected with NFI-C-expressing or NFI-C-siRNA
constructs. Data are presented as the mean ± SD of triplicate experiments. (C) Migration was analyzed by wound healing assays in MCF7 cell
transfected with NFI-C-expressing or NFI-C-siRNA constructs or treated with TGF-β (Magnification: 400×). (D) The invasion capacity of MCF7 cells,
which were transfected with NFI-C-expressing or NFI-C-siRNA constructs, or treated with TGF-β was determined by matrigel-coated transwell
assays. Average cell counts from representative fields for each condition are given as mean ± S.D. (E) The effect of NFI-C on EMT of breast cancer
cells was analyzed using gene expression data collected from atypical ductal hyperplasia with or without breast cancer in the Gene Expression
Omnibus (GEO) database (GSE 2429). The mean and standard variants were calculated from four biological replicates for both activity and mRNA
levels of NFI-C, KLF4, E-cadherin, TIAM1 (invasion activator), and SCAI (invasion suppressor). * denotes values significantly different from the control
(P < 0.01). ADH: Atypical ductal hyperplasia.
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ducing target of the KLF4/E-cadherin pathway and plays a
significant role in EMT repression.
NFI-C and NFI-X influence KLF4 transcription
NFI family members inhibit tumorigenesis by regulating
oncogenic transcriptional factors such as brain fatty acid-
binding protein (B-FABP) and JUN proteins [29-31]. To
investigate the function of the four NFI factors on EMT/
MET regulation, we examined the effects of NFI family
member overexpression on KLF4 and E-cadherin pro-
moter activity. Expression of each of the NFI isoforms wasconfirmed by western blotting with the anti-HA antibody
after transfection. Overexpression of NFI-C and NFI-X
resulted in a statistically significant increase in KLF4
and E-cadherin transcriptional activity in MCF7 breast
cancer cells, while NFI-A and NFI-B overexpression did
not (Figure 4).
Next, expression vectors encoding NFI-A, NFI-B, NFI-C,
or NFI-X were co-transfected with E-cadherin reporter
constructs into MCF7 cells. Transfection of NFI-C and
NFI-X constructs significantly enhanced KLF4 and E-
cadherin promoter activity, suggesting that these two iso-
forms function as transcriptional activators of KLF4 and
Figure 4 Effects of NFI family members on the expression of KLF4 and E-cadherin. (A) Expression of HA, KLF4, and E-cadherin proteins was
analyzed by western blotting (left panel) and quantified (right panel) in MCF7 cells transfected with HA-tagged-NFI-A, −NFI-B, −NFI-C, or -NFI-X
expressing constructs. (B) The transcriptional activity of the E-cadherin promoters was evaluated by luciferase assay in MCF7 cells transfected
with NFI-A-, NFI-B-, NFI-C-, or NFI-X-expressing constructs. The data are presented as the mean ± SD of triplicate experiments. * denotes values
significantly different from the control (P < 0.01).
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B–expressing constructs did not noticeably activate KLF4
or E-cadherin (Figure 4B).
NFI-C and E-cadherin were strongly immunostained in
normal human breast tissue
NFI-C was stained stronger in normal glandular cells
than tumor cells [14]. To assess the expression pattern
of NFI-C and E-cadherin in breast tumors, we examined
the NFI-C and E-cadherin protein expression in human
breast cancer. Normal breast cells and early stage tumor
cells uniformly stained strongly positive for NFI-C and
E-cadherin protein (Figure 5A, C). In contrast, malignant
ductal carcinoma cells revealed weak positive staining for
anti-NFI-C and -E-cadherin (Figure 5B, D). These results
suggested that NFI-C is an important factor for the epi-
thelial character in vivo in that NFI-C and E-cadherin is
expressed in normal human breast tissues, but its expres-
sion is reduced in malignant human breast tumors.
Discussion
Unlike epithelial cells, which are stationary and character-
ized by apical-basal polarity, tight junctions, and expres-
sion of cell-cell adhesion markers such as E-cadherin,
mesenchymal cells do not make mature cell-cell contacts,
can invade through the ECM, and express markers such
as Vimentin, Fibronectin, N-cadherin, Twist, and Snail[32,33]. Moreover, induced pluripotent stem cells (iPSCs)
are derived from mouse embryonic fibroblasts (MEFs) by
MET at the early stage of reprogramming [34]. These re-
sults suggest that MET is associated with normal develop-
ment, cancer metastasis, inhibiting cancer progression,
stem cell generation, and induced pluripotent stem cell re-
programming. However, relatively little is known regard-
ing MET, compared to the extensive studies of EMT in
dental organ development and tumor metastasis.
Recently, researchers have investigated MET pathways
as potential therapeutic targets in organ regeneration
and the prevention of metastases [35]. TGF-β, an import-
ant inducer of EMT, degrades NFI-C, whereas NFI-C in-
duces dephosphorylation of p-Smad2/3, a TGF-β signaling
molecule, in odontoblasts and breast cancer cells [16].
Thus, NFI-C counteracts EMT, motility, invasiveness, and
tumor growth [14]. KLF4, an important inducer of MET,
activates the epithelial program by triggering E-cadherin
expression and induces MET in normal mammary epithe-
lial cells and breast cancer cells [35].
E-cadherin and N-cadherin, both expressed in pulp
cells during odontogenesis, are involved in the regulation
of various biological processes, such as cell recognition,
intercellular communication, cell fate, cell polarity, bound-
ary formation, and morphogenesis [36,37]. In NFI-C −/−
mice, KLF4 mRNA expression is significantly decreased
compared to wild-type cells. NFI-C binds directly to the
Figure 5 Expression of NFI-C and E-cadherin protein in malignant human breast tissue by immunohistochemistry. (A) Expression of
NFI-C in a benign breast ductile. (B) Expression of NFI-C in a malignant ductal carcinoma. (C) Expression of E-cadherin in early stage tumor cells.
(D) Expression of E-cadherin in a malignant ductal carcinoma. Scale bars = 200 μm.
Figure 6 Model for the function of NFI-C and KLF4
during tumorigenesis.
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ity, thereby regulating Dmp1 and DSPP expression during
odontoblast differentiation, and then promoting mineral-
ized nodule formation in MDPC-23 cells. It is involved
with important signaling pathways during dentinogenesis:
the NFI-C-KLF4-Dmp1-Dspp and the NFI-C-KLF4-E-
cadherin pathways in odontoblasts [17]. Consistent with
these observations, odontoblastic MDPC-23 cells show op-
posite patterns of NFI-C/E-cadherin and TGF-β/N-cadherin
expression [16,17].
In the present study, NFI-C was shown to regulate KLF4,
a MET inducer, and subsequently controlled E-cadherin ex-
pression in normal mammary epithelial cells (MCF10A)
and breast cancer cells (MCF7). Consistent with previous
investigations of odontoblasts, NFI-C also induced MET in
breast cancer cells via upregulation of KLF4 and E-cadherin
and down-regulation of Slug, a dominant regulator of
EMT initiation. NFI-C suppressed migration and invasion
in breast cancer cells. In contrast, NFI-C inactivation by
siRNA promoted breast cancer cell migration and inva-
sion. These results suggest that NFI-C induces MET in
cell types other than odontoblasts, such as cancer cells,
through regulation of the KLF4-E-cadherin axis, thus pre-
venting cancer cell migration and invasion.
NFI family members (NFI-A, NFI-B, NFI-C, and NFI-X)
exhibit promoter-specific differences in their maximal
transcriptional activation potentials due to differences in
their carboxy-terminal regions [38]. NFI proteins exhibit
cell type- and promoter-specific differences in their re-
pression properties, with NFI-C and NFI-X, but not
NFI-a and NFI-B, repressing the mouse mammary tumorvirus (MMTV) promoter in HeLa cells. NFI-C-mediated
repression occurs by interference with coactivator
(e.g., p300/CBP or SRC-1A) function at the MMTV pro-
moter [30]. Although it is widely accepted that NFI pro-
teins differ in their repression and activation potentials,
their ability to regulate transcription is poorly understood.
In the present study, NFI-C and NFI-X influenced KLF4
transcription but NFI-A and NFI-B did not. NFI-C and
NFI-X likely regulate KLF4 because the DNA-binding
affinities of NFI-C and NFI-X were higher than those of
NFI-a and NFI-B; however, no direct evidence supports
this notion.
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As summarized in Figure 6, NFI-C was strongly expressed
in normal mammary gland cells. NFI-C increased the
expression of KLF4 and E-cadherin, and led to a more
pronounced epithelial cell phenotype. In contrast, NFI-C
knock-down induced migration and invasion. These re-
sults demonstrate that NFI-C is essential for the main-
tenance of epithelial differentiation and is required to
reduce EMT and metastasis by regulation of KLF4 and
E-cadherin expression. This work is the first to inves-
tigate the NFI-C-KLF4-E-cadherin signaling pathway
in breast cancer cells, as well as their functional im-
plications during tumorigenesis. This information will
lead to a comprehensive understanding of the role of
NFI-C in cancer.
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